Mental Disorders in Young Adults from Families with the Presenilin-1 Gene Mutation E280A in the Preclinical Stage of Alzheimer's Disease.
Alzheimer’s disease
Presenilin-1
behavioral symptoms
mental disorders
Journal
Journal of Alzheimer's disease reports
ISSN: 2542-4823
Titre abrégé: J Alzheimers Dis Rep
Pays: Netherlands
ID NLM: 101705500
Informations de publication
Date de publication:
29 Aug 2019
29 Aug 2019
Historique:
entrez:
23
11
2019
pubmed:
23
11
2019
medline:
23
11
2019
Statut:
epublish
Résumé
There are forms of Alzheimer's disease (AD) that have an autosomal dominant inheritance pattern; one of them is caused by the E280A mutation in the gene that codes for Presenilin-1 ( To determine whether having the mutation E280A in A psychiatric evaluation was made to 120 people belonging to families with a history of early onset AD. Of these, 62 carried the E280A mutation in No statistically significant differences were found in the frequency of any mental disorder between the group of carriers and non-carriers of the mutation (Hazard Ratio: 0.80, 95% CI 0.49 to 1.31); nor were differences observed when evaluating specific disorders. The E280A mutation does not increase the risk of mental disorders before the age of 30 in the relatives of people affected by familial AD. Studies with larger sample sizes are required to assess the risk of low incidence mental disorders.
Sections du résumé
BACKGROUND
BACKGROUND
There are forms of Alzheimer's disease (AD) that have an autosomal dominant inheritance pattern; one of them is caused by the E280A mutation in the gene that codes for Presenilin-1 (
OBJECTIVE
OBJECTIVE
To determine whether having the mutation E280A in
METHODS
METHODS
A psychiatric evaluation was made to 120 people belonging to families with a history of early onset AD. Of these, 62 carried the E280A mutation in
RESULTS
RESULTS
No statistically significant differences were found in the frequency of any mental disorder between the group of carriers and non-carriers of the mutation (Hazard Ratio: 0.80, 95% CI 0.49 to 1.31); nor were differences observed when evaluating specific disorders.
CONCLUSION
CONCLUSIONS
The E280A mutation does not increase the risk of mental disorders before the age of 30 in the relatives of people affected by familial AD. Studies with larger sample sizes are required to assess the risk of low incidence mental disorders.
Identifiants
pubmed: 31754656
doi: 10.3233/ADR-190139
pii: ADR190139
pmc: PMC6839534
doi:
Types de publication
Journal Article
Langues
eng
Pagination
241-250Informations de copyright
© 2019 – IOS Press and the authors. All rights reserved.
Déclaration de conflit d'intérêts
A. Villalba, J. García, R. Cuastumal and D.C. Aguirre have nothing to disclosure. C. Ramos reports the following (pertinent for the last two years): grant and contract support from the NIA, Genentech/Roche, and an anonymous foundation to develop the Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer’s Disease - API ADAD - Registry since 2015 and she helps to conduct the API ADAD Trial in Colombia. D. Aguillón reports the following (pertinent for the last two years): grant and contract support from the National Institute on Aging - NIA -, Genentech/Roche, and an anonymous foundation to develop the API ADAD Registry since 2017 and he helps to conduct the API ADAD Trial in Colombia. L. Madrigal receives grant and contract support from the NIA, Genentech/Roche, and an anonymous foundation to develop the API ADAD Registry since 2013 and she helps to conduct the API ADAD Trial in Colombia. F. Lopera receives grand and contract support from the NIA, Genentech/Roche, and an anonymous foundation to develop the API ADAD Registry since 2013 and he is the principal investigator of the API ADAD Trial in Colombia.
Références
JAMA Neurol. 2015 Aug;72(8):912-9
pubmed: 26121081
Neuroscience. 2018 Feb 1;370:181-190
pubmed: 28729061
Postgrad Med. 2017 Apr;129(3):375-381
pubmed: 28271921
Lancet Neurol. 2016 Dec;15(13):1326-1335
pubmed: 27777022
Psychol Bull. 2015 Jul;141(4):858-900
pubmed: 25915035
EMBO Mol Med. 2016 Jun 01;8(6):595-608
pubmed: 27025652
Rev Colomb Psiquiatr. 2017 Jul - Sep;46(3):129-139
pubmed: 28728796
Int J Geriatr Psychiatry. 2013 Mar;28(3):276-83
pubmed: 22552913
J Formos Med Assoc. 2016 Feb;115(2):67-75
pubmed: 26337232
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Clin Interv Aging. 2016 May 17;11:665-81
pubmed: 27274215
Alzheimers Dement. 2017 Jan;13(1):1-7
pubmed: 27583652
N Engl J Med. 2010 Jan 28;362(4):329-44
pubmed: 20107219
Arch Gen Psychiatry. 1994 Nov;51(11):849-59; discussion 863-4
pubmed: 7944874
Biomedica. 2004 Mar;24(1):56-62
pubmed: 15239602
Lancet Neurol. 2010 Nov;9(11):1118-27
pubmed: 20934914
Lancet Neurol. 2016 Dec;15(13):1317-1325
pubmed: 27777020
JAMA Neurol. 2016 Apr;73(4):431-8
pubmed: 26902171
J Health Psychol. 2019 Sep;24(11):1574-1580
pubmed: 29139312
Lancet. 2011 Mar 19;377(9770):1019-31
pubmed: 21371747
Front Neurol. 2015 Jun 29;6:142
pubmed: 26175713
Nat Med. 1996 Oct;2(10):1146-50
pubmed: 8837617
J Alzheimers Dis. 2012;32(1):1-12
pubmed: 22766738
Mol Aspects Med. 2015 Jun-Oct;43-44:25-37
pubmed: 26049034
Int J Geriatr Psychiatry. 2013 Aug;28(8):795-803
pubmed: 23147419
Curr Neurol Neurosci Rep. 2014 Nov;14(11):499
pubmed: 25217249
Hum Mutat. 1997;10(3):186-95
pubmed: 9298817
Aten Primaria. 2012 Jul;44(7):411-6
pubmed: 22055916
Int J Geriatr Psychiatry. 2011 Oct;26(10):1019-29
pubmed: 21905097
Mol Neurobiol. 2016 Sep;53(7):4833-64
pubmed: 26351077
Can J Psychiatry. 2011 Jul;56(7):408-17
pubmed: 21835104
Ther Clin Risk Manag. 2015 Jan 23;11:115-26
pubmed: 25670901
Ann Neurol. 2010 Dec;68(6):865-75
pubmed: 21194156
Assessment. 2017 Dec;24(8):999-1007
pubmed: 26951323
Lancet Neurol. 2011 Mar;10(3):213-20
pubmed: 21296022
JAMA. 1997 Mar 12;277(10):793-9
pubmed: 9052708
Am J Med Genet B Neuropsychiatr Genet. 2017 Jan;174(1):5-26
pubmed: 27943641
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Brain. 2015 Apr;138(Pt 4):1036-45
pubmed: 25688083
Psychophysiology. 2016 Sep;53(9):1386-97
pubmed: 27273802
Clin Psychol Rev. 2015 Mar;36:28-41
pubmed: 25638755
Int Psychogeriatr. 2003 Dec;15(4):337-49
pubmed: 15000414